U.S. onlyEducational navigation. Verify coverage and assistance with the official insurer, program, or treatment site.

How do I get Lytenava through my insurance?

Lytenava · bevacizumab-vikg · FDA-approved ophthalmic bevacizumab

Lytenava coverage navigator.

FDA approved July 2026 for neovascular (wet) age-related macular degeneration. Coverage, product preference, U.S. commercial availability and coding are still developing.

New-product note: FDA approved July 24, 2026; Outlook Therapeutics has announced a planned U.S. commercial launch before the end of 2026. Verify current availability and coding.

No account, member ID, name, date of birth or email is needed. Your selections stay in this page session.

1
WHY IS THIS MEDICINE BEING GIVEN?

Choose the diagnosis / reason.

Coverage rules can change by diagnosis and sometimes by formulation.

FINANCIAL HELP

Find help with your out-of-pocket costs.

Use the official support program below to check savings, patient-assistance, or access options that may apply to you.

Outlook Therapeutics — LYTENAVA product overview →
IF COVERAGE GETS STUCK

The medicine may be only part of the problem.

Use the playbook that matches what is blocking treatment, then verify the current rule with the insurer, program or treatment site.

Build a next-step plan →

Important

MedicineCostHelp is an educational navigation tool, not an insurer and not a coverage determination. Medical policies, billing codes, product preferences, availability and benefit placement can change. Sources were reviewed 2026-09-11. Verify the current official source before acting.

Build a next-step action plan →

How we review sources → · Report outdated info →